La cadena de opciones muestra datos clave de las opciones de acciones de TruGolf Holdings a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para TruGolf Holdings..

TruGolf Holdings (NASDAQ:TRUG) Bolsa, Cadena de Opciones

TruGolf Holdings

TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games (including Links, a sports game for PC), hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Twilio sube un 18,5% tras superar expectativas de ingresos. Explora los movimientos clave del mercado previo de hoy.

Acciones de Twilio (TWLO) se disparan más de un 18%; 20 acciones que se mueven en el premercado de EE.UU.

TruGolf Holdings, Inc. - Class A Common Stock

TruGolf Holdings Inc

TRUGOLF HLDGS INC RT

Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) is gearing up to announce its quarterly earnings on Monday, 2025-08-04. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Ardelyx will report an earnings per share (EPS) of $-0.13.
Ardelyx bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.09, leading to a 24.5% drop in the share price the following trading session.
Here's a look at Ardelyx's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.08</td>
<td>0</td>
<td>-0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.17</td>
<td>0.02</td>
<td>0</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-24.0%</td>
<td>-12.0%</td>
<td>4.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754078470_0.png" alt="eps graph" />
<h3>Market Performance of Ardelyx's Stock</h3>
Shares of Ardelyx were trading at $4.24 as of July 31. Over the last 52-week period, shares are down 25.3%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Insights Shared by Analysts on Ardelyx</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Ardelyx.
The consensus rating for Ardelyx is Buy, derived from 1 analyst ratings. An average one-year price target of $10.0 implies a potential 135.85% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of MiMedx Group, Iovance Biotherapeutics and GRAIL, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for MiMedx Group, with an average 1-year price target of $11.5, suggesting a potential 171.23% upside.</li>
<li>Analysts currently favor an Buy trajectory for Iovance Biotherapeutics, with an average 1-year price target of $13.43, suggesting a potential 216.75% upside.</li>
<li>Analysts currently favor an Buy trajectory for GRAIL, with an average 1-year price target of $43.0, suggesting a potential 914.15% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
In the peer analysis summary, key metrics for MiMedx Group, Iovance Biotherapeutics and GRAIL are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ardelyx</td>
<td>Buy</td>
<td>61.04%</td>
<td>$61.81M</td>
<td>-25.80%</td>
</tr>
<tr>
<td>MiMedx Group</td>
<td>Outperform</td>
<td>13.07%</td>
<td>$79.92M</td>
<td>4.59%</td>
</tr>
<tr>
<td>Iovance Biotherapeutics</td>
<td>Buy</td>
<td>6798.46%</td>
<td>$-417K</td>
<td>-15.72%</td>
</tr>
<tr>
<td>GRAIL</td>
<td>Buy</td>
<td>19.15%</td>
<td>$-19.93M</td>
<td>-4.32%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Ardelyx ranks at the bottom for Revenue Growth and Gross Profit, with negative values in both metrics. It also has the lowest Return on Equity among its peers. However, Ardelyx has a higher Consensus rating compared to its peers.
<h3>Delving into Ardelyx's Background</h3>
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
<h3>Ardelyx: Delving into Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Ardelyx's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 61.04%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ardelyx's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -55.51% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Ardelyx's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -25.8%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -9.73%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.06.
<a href="https://www.benzinga.com/quote/ARDX/earnings">To track all earnings releases for Ardelyx visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ARDX

What to Expect from Ardelyx's Earnings

In the current market session, Alpha Metallurgical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) share price is at $117.50, after a 0.48% drop. Over the past month, the stock went up by 2.26%, but over the past year, it actually fell by 54.09%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1754078466_0.png" alt="Past Year Chart" />

<h3>Comparing Alpha Metallurgical P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Alpha Metallurgical has a better P/E ratio of 57.88 than the aggregate P/E ratio of 27.58 of the Metals &amp; Mining industry. Ideally, one might believe that Alpha Metallurgical Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1754078466_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Alpha Metallurgical

Analysts' ratings for Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Valaris, presenting an average target of $45.17, a high estimate of $52.00, and a low estimate of $37.00. This upward trend is evident, with the current average reflecting a 8.84% increase from the previous average price target of $41.50.
<img src="https://www.benzinga.com/files/images/story/2025/1754078462_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Valaris among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Valaris. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Valaris compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Valaris's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Valaris's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VAL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Valaris analyst ratings.</a>
<h2>All You Need to Know About Valaris</h2>
Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.
<h3>A Deep Dive into Valaris's Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Challenges: Valaris's revenue growth over 3M faced difficulties. As of 30 June, 2025, the company experienced a decline of approximately -0.89%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.
Net Margin: Valaris's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 18.71%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Valaris's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.07% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Valaris's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.59%, the company showcases efficient use of assets and strong financial health.
Debt Management: Valaris's debt-to-equity ratio is below the industry average. With a ratio of 0.46, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 6 Analyst Ratings Have To Say About Valaris

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 22 uncommon options trades for Regeneron Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 31%, bearish.
Out of all of the special options we uncovered, 10 are puts, for a total amount of $724,710, and 12 are calls, for a total amount of $505,746.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $290.0 to $700.0 for Regeneron Pharmaceuticals during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Regeneron Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals's whale trades within a strike price range from $290.0 to $700.0 in the last 30 days. 
<h3>Regeneron Pharmaceuticals 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754078452_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/18/26</td>
<td>$81.9</td>
<td>$74.0</td>
<td>$77.98</td>
<td>$560.00</td>
<td>$116.9K</td>
<td align="right">6</td>
<td align="right">0</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/01/25</td>
<td>$26.8</td>
<td>$23.0</td>
<td>$23.0</td>
<td>$600.00</td>
<td>$115.0K</td>
<td align="right">80</td>
<td align="right">0</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/22/25</td>
<td>$20.0</td>
<td>$16.1</td>
<td>$20.0</td>
<td>$560.00</td>
<td>$114.0K</td>
<td align="right">60</td>
<td align="right">1</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/01/25</td>
<td>$39.8</td>
<td>$31.0</td>
<td>$35.4</td>
<td>$600.00</td>
<td>$106.2K</td>
<td align="right">80</td>
<td align="right">50</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/18/26</td>
<td>$80.4</td>
<td>$74.0</td>
<td>$77.0</td>
<td>$560.00</td>
<td>$77.0K</td>
<td align="right">6</td>
<td align="right">25</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Having examined the options trading patterns of Regeneron Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Regeneron Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,309,784, with REGN's price up by 2.02%, positioned at $556.49.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>Professional Analyst Ratings for Regeneron Pharmaceuticals</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $729.33.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Regeneron Pharmaceuticals, targeting a price of $850. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Regeneron Pharmaceuticals with a target price of $584. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Regeneron Pharmaceuticals, maintaining a target price of $754. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Regeneron Pharmaceuticals with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

REGN

Smart Money Is Betting Big In REGN Options

Financial giants have made a conspicuous bearish move on Accenture. Our analysis of options history for Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) revealed 27 unusual trades.
Delving into the details, we found 29% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 17 were puts, with a value of $948,071, and 10 were calls, valued at $504,272.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $210.0 to $350.0 for Accenture over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Accenture's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Accenture's significant trades, within a strike price range of $210.0 to $350.0, over the past month.
<h3>Accenture Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754078447_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$88.4</td>
<td>$86.2</td>
<td>$87.6</td>
<td>$350.00</td>
<td>$254.0K</td>
<td align="right">21</td>
<td align="right">0</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$24.6</td>
<td>$24.3</td>
<td>$24.6</td>
<td>$270.00</td>
<td>$128.0K</td>
<td align="right">23</td>
<td align="right">53</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/18/26</td>
<td>$45.5</td>
<td>$44.0</td>
<td>$44.75</td>
<td>$290.00</td>
<td>$93.9K</td>
<td align="right">12</td>
<td align="right">24</td>
</tr>
<tr>
<td>ACN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$36.0</td>
<td>$32.8</td>
<td>$35.0</td>
<td>$260.00</td>
<td>$63.0K</td>
<td align="right">77</td>
<td align="right">21</td>
</tr>
<tr>
<td>ACN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$53.2</td>
<td>$51.7</td>
<td>$52.67</td>
<td>$310.00</td>
<td>$57.9K</td>
<td align="right">125</td>
<td align="right">11</td>
</tr>
</tbody>
</table>

<h3>About Accenture</h3>
Accenture is a leading IT services firm that provides consulting, system integration, and business process outsourcing to enterprises around the world. Customers of Accenture come from a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture is the world's largest professional services company by headcount with around 800,000 employees in over 120 countries.
After a thorough review of the options trading surrounding Accenture, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Accenture</h3>
<ul>
<li>With a trading volume of 4,174,233, the price of ACN is down by -0.99%, reaching $264.45.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 55 days from now.</li>
</ul>
<h3>Expert Opinions on Accenture</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $286.67.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Deutsche Bank has revised its rating downward to Hold, adjusting the price target to $290. 
&#x2A; Reflecting concerns, an analyst from HSBC lowers its rating to Reduce with a new price target of $240. 
&#x2A; Reflecting concerns, an analyst from Evercore ISI Group lowers its rating to Outperform with a new price target of $330.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Accenture, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

What the Options Market Tells Us About Accenture

Watsco's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) short percent of float has risen 7.13% since its last report. The company recently reported that it has 2.50 million shares sold short, which is 9.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.54 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Watsco Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754078441_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Watsco has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Watsco's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Watsco's peer group average for short interest as a percentage of float is 5.09%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What's Driving the Market Sentiment Around Watsco?

Benzinga's options scanner just detected over 9 options trades for Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) summing a total amount of $583,322.
At the same time, our algo caught 5 for a total amount of 497,671.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $29.0 for Norwegian Cruise Line over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Norwegian Cruise Line's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Norwegian Cruise Line's significant trades, within a strike price range of $20.0 to $29.0, over the past month.
<h3>Norwegian Cruise Line Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754078442_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCLH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$3.95</td>
<td>$3.85</td>
<td>$3.85</td>
<td>$25.00</td>
<td>$288.8K</td>
<td>1.8K</td>
<td align="right">560</td>
</tr>
<tr>
<td>NCLH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$1.39</td>
<td>$1.36</td>
<td>$1.39</td>
<td>$20.00</td>
<td>$104.1K</td>
<td>1.1K</td>
<td align="right">1</td>
</tr>
<tr>
<td>NCLH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$3.35</td>
<td>$3.3</td>
<td>$3.35</td>
<td>$25.00</td>
<td>$71.3K</td>
<td>700</td>
<td align="right">22</td>
</tr>
<tr>
<td>NCLH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$0.68</td>
<td>$0.65</td>
<td>$0.68</td>
<td>$26.00</td>
<td>$54.4K</td>
<td>14.1K</td>
<td align="right">304</td>
</tr>
<tr>
<td>NCLH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$2.66</td>
<td>$2.52</td>
<td>$2.53</td>
<td>$20.00</td>
<td>$50.4K</td>
<td>867</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Norwegian Cruise Line</h3>
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 70,000). It operates 33 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 12 passenger vessels on order among its brands through 2036, representing 37,500 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
Having examined the options trading patterns of Norwegian Cruise Line, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Norwegian Cruise Line</h3>
<ul>
<li>Currently trading with a volume of 16,586,658, the NCLH's price is down by -1.76%, now at $25.11. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 90 days.</li>
</ul>
<h3>Expert Opinions on Norwegian Cruise Line</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $29.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from TD Cowen has revised its rating downward to Buy, adjusting the price target to $31. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Norwegian Cruise Line with a target price of $31. 
&#x2A; An analyst from Mizuho has decided to maintain their Outperform rating on Norwegian Cruise Line, which currently sits at a price target of $29. 
&#x2A; An analyst from Susquehanna persists with their Neutral rating on Norwegian Cruise Line, maintaining a target price of $25. 
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Norwegian Cruise Line, targeting a price of $29. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Norwegian Cruise Line, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

NCLH

Check Out What Whales Are Doing With NCLH

Alibaba Gr Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) short percent of float has fallen 3.8% since its last report. The company recently reported that it has 30.37 million shares sold short, which is 1.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.89 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Alibaba Gr Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754078436_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alibaba Gr Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Alibaba Gr Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Alibaba Gr Hldgs's peer group average for short interest as a percentage of float is 10.44%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

BABA

What's Driving the Market Sentiment Around Alibaba Gr Hldgs?

Strategy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NYSE">MSTR</a>) short percent of float has risen 7.53% since its last report. The company recently reported that it has 25.59 million shares sold short, which is 9.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Strategy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754078431_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Strategy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Strategy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Strategy's peer group average for short interest as a percentage of float is 3.01%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MSTR

What's Driving the Market Sentiment Around Strategy?

Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) has outperformed the market over the past 20 years by 1.45% on an annualized basis producing an average annual return of 9.87%. Currently, Cheniere Energy has a market capitalization of $51.90 billion. 
Buying $100 In LNG: If an investor had bought $100 of LNG stock 20 years ago, it would be worth $662.55 today based on a price of $234.00 for LNG at the time of writing.
<h3>Cheniere Energy's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754078430_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Cheniere Energy 20 Years Ago Would Be Worth Today

Citigroup analyst Paul Lejuez maintains Columbia Sportswear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLM#NASDAQ">COLM</a>) with a Neutral and lowers the price target from $64 to $61.

Price Target

COLM

Citigroup Maintains Neutral on Columbia Sportswear, Lowers Price Target to $61

<a href="https://www.globenewswire.com/Tracker?data=QI748aDc-twczX81LbFBAldu1iGsg7hT7qgfhbQwSqPXRx_ePKhbkO1urb_P2_DGBJ_CXtXr_KKC3RW1jm_Ncw==">Tevogen</a> ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>), today released a letter to stockholders.
Dear Fellow Stockholders,
Tevogen has rapidly evolved from a biotechnology innovator into a dynamic enterprise expanding into artificial intelligence through Tevogen.AI. Our mission remains steadfast: delivering clinically impactful, economically accessible therapies by leveraging cutting-edge science and technology.
Tevogen has become a recognized name for its business philosophy of social responsibility, patient affordability and cost efficiency. In under five years, we validated our proprietary ExacTcell&#x2122; platform, completed successful proof-of-concept clinical trial of the platforms first product, established drug discovery R&amp;D center&nbsp;— currently in the process of establishing our own GMP cell manufacturing facility, expanded corporate infrastructure, built a robust intellectual property portfolio, and established one of the pioneering AI initiatives in the industry&nbsp;— assets of significant value, while maintaining 74% insider equity ownership.
With the successful launch of our proprietary AI-driven PredicTcell&#x2122; platform, we've significantly enhanced target discovery efficiency. Strategic partnerships with global technology leaders, such as Microsoft and Databricks, have accelerated our progress. Recent patent filings further secure our intellectual property in AI-driven predictive modeling, positioning us at the forefront of innovation.
Importantly, Tevogen Bio is well capitalized, having access to necessary funding we may require to fully execute our current growth strategy, including the accelerated development of Tevogen.AI. While the sector faces significant challenges, our company continues to grow, underscoring the foundational strength of our company.
We deeply appreciate your continued support as we work toward our vision of transforming healthcare through democratizing access. It feels good to be part of this growth story and am grateful to my colleagues at Tevogen for their exceptional expertise, dedication, and, above all, their compassion for others.
Sincerely,
Ryan Saadi, MD, MPH Founder and CEO, Tevogen Bio

Guidance

Management

TVGN

Tevogen Bio Issues Letter to Stockholders Highlighting Rapid Growth, AI Expansion, And Capital Position

Psyence Biomedical Shares Halted On Circuit Breaker To The Downside, Stock Now Down -44.1%

<a href="https://www.sec.gov/newsroom/press-releases/2025-103-sec-creates-task-force-tap-artificial-intelligence-enhanced-innovation-efficiency-across-agency" title="https://www.sec.gov/newsroom/press-releases/2025-103-sec-creates-task-force-tap-artificial-intelligence-enhanced-innovation-efficiency-across-agency">https://www.sec.gov/newsroom/press-releases/2025-103-sec-creates-task-force-tap-artificial-intelligence-enhanced-innovation-efficiency-across-agency</a>

Macro Economic Events

Politics

Economics

General

'SEC Creates Task Force to Tap Artificial Intelligence for Enhanced Innovation and Efficiency Across the Agency' - SEC

Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and raises the price target from $46 to $52.

APLS

Citigroup Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $52

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) with a Buy and raises the price target from $49 to $52.

LENZ

Citigroup Maintains Buy on LENZ Therapeutics, Raises Price Target to $52

As a bill to ban members of Congress from trading stocks and options makes its way through Congress, new financial disclosures from a senator could show why the public<a href="https://www.benzinga.com/general/politics/24/05/39096827/exclusive-khanna-says-shameful-congress-members-profited-from-stocks-calls-for-trading-ban-makin"> has grown tired</a> of elected officials being able to profit from trading.
What Happened: New financial disclosures from Senator Markwayne Mullin (R-Okla.) show the lawmaker making multiple stock purchases back in January 2023 and waiting until July 2025 to disclose the transactions, as reported by <a href="https://www.benzinga.com/gov-trades/members/markwayne-mullin">Benzinga's Government Trades page.</a>
Benzinga reached out to Mullin's offices in Oklahoma and Washington, D.C., about the trades and did not hear back at the time of publication.
The transactions were made on Jan. 3, 2023 and disclosed on July 30, 2025. Each stock purchase was for a value of $1,000 to $15,000, and it is unclear if Mullin still owns any of the positions.
Below is a breakdown of each stock purchase, showing the trading range on January 3, 203, the current share price, and the return calculated from the high price on the purchase date.
<ul class="wp-block-list">
<li>Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>): $282.77 to $300.00, $285.37 now, -5.1%</li>
<li>Instructure Holdings (was INST, taken private in 2024): $24.48 to $26.32, private at $23.60, -10.3%</li>
<li>Hubbell Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>): $232.01 to $237.53, $424.41 now, +78.7%</li>
<li>Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>): $129.12 to $133.53, $313.13 now, +134.5%</li>
<li>EXLService Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NASDAQ">EXLS</a>): $34.09 to $34.75, $42.38 now, +22.0%</li>
<li>Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>): $58.30 to $59.12, $71.03 now, +20.1%</li>
<li>Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>): $32.38 to $35.50, $44.79 now, +26.2%</li>
</ul>
As you can see most of the stocks are down or up around 20% after two and a half years. However, two of the stocks have decent size gains, including Fabrinet, up 134.5% since the time of Mullin's purchase.
What makes the transactions stand out is the delay in filing the disclosures. The STOCK Act requires members of Congress to disclose stock and option purchases and sales within 45 days. Obviously, the two-and-a-half-year period falls well outside the 45 days.
Current rules show that Mullin will be fined $200 to $500 for violating the STOCK Act, a small price to pay for not following the rules.
"We just caught new STOCK Act violations by Senator Markwayne Mullin. He disclosed trades that were made over two years ago," Quiver Quant <a href="https://x.com/QuiverQuant/status/1950752535851008064">tweeted</a>.
Quiver Quant also shows the date of purchase as Jan. 3, 2023, and the disclosure being made on July 30, 2025.
Mullin is an ally of President Donald Trump and a frequent guest on political news programs.
Did You Know?
<ul class="wp-block-list">
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent080125">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Mullin's trading activity has been flagged before by Benzinga and elsewhere. Earlier this year, Mullin <a href="https://www.benzinga.com/news/politics/25/06/45908750/gop-senator-on-armed-services-committee-buys-this-defense-stock-in-potential-conflict-of-interest">disclosed buying stock </a>in L3 Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>), a defense company. The transaction comes with Mullin serving on the Committee on Armed Services, which could provide him with inside information about government defense purchases.
A report from <a href="https://www.newsweek.com/congress-stock-trading-mullin-1993427">Newsweek </a>previously accused Mullin of violating the STOCK Act and making questionable trades related to another committee assignment.
Mullin's disclosures come after Sen. Josh Hawley (R-Mo.)<a href="https://www.benzinga.com/politics/25/04/45077654/bill-named-after-nancy-pelosi-could-ban-congress-members-from-trading-stocks-what-you-need-to-know-about-the-pelosi-act" target="_blank" rel="noreferrer noopener"> introduced the</a> Preventing Elected Leaders from Owning Securities and Investments Act, or PELOSI Act, based on the first letter of each of the main words. The name targets Congresswoman and former Speaker of the House Nancy Pelosi (D-Calif.).
The bill made its way out of committee and could come before Congress for a vote.
Benzinga<a href="https://www.benzinga.com/trading-ideas/25/05/45552223/exclusive-congress-trading-ban-sees-huge-support-in-reader-poll-heres-the-percent-that-say-let-them-keep-trading-stocks" target="_blank" rel="noreferrer noopener">&nbsp;recently polled readers</a>&nbsp;to see where they stand on a potential ban on Congress trading.
"Should members of Congress be allowed to buy and sell stocks, options and ETFs?" Benzinga asked.
These were the results:
<ul class="wp-block-list">
<li>They should not be allowed to trade stocks, options or ETFs:&nbsp;43%</li>
<li>They should be allowed to trade as long as they report within 24 hours:&nbsp;24%</li>
<li>They should only be allowed to trade ETFs and mutual funds:&nbsp;14%</li>
<li>They should be allowed to trade as long as they report in 45 days: 11%</li>
<li>They should only be allowed to trade stocks: 8%</li>
</ul>
The poll found that 43% of readers support an outright ban on members of Congress trading stocks, options, or ETFs. Eleven percent voted to leave the current rules unchanged, with a 45-day disclosure window.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/01/42860759/10-best-stock-traders-in-congress-in-2024-where-do-nancy-pelosi-pete-sessions-susan-collins-marjorie-taylor-greene-rank">Top 10 Stock Traders In Congress For 2024: How Nancy Pelosi, Pete Sessions, Susan Collins, Marjorie Taylor Greene Rank</a></li>
</ul>
Photo: Shutterstock

CELH

CTVA

EXLS

HUBB

PODD

Senator Mullin Discloses Stock Trades 2.5 Years After They Were Made, Including One Up 134.5%

WIIM

NuScale Power shares are trading lower. Fluor reportedly said it will convert its NuScale Class B shares into Class A shares.

Shares of Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) are falling Friday afternoon, caught in a broad market sell-off driven by a one-two punch of <a href="https://www.benzinga.com/markets/economic-data/25/08/46792479/july-nonfarm-payrolls-trump-powell-labor-market">alarming U.S. economic data</a> and an escalation in geopolitical tensions.
What To Know: The primary catalyst was a weak July jobs report. The U.S. economy added a mere 73,000 jobs, far below the 190,000 expected, while prior months&#8217; figures were revised down by a combined 258,000. For a bellwether bank like Bank of America, such a clear sign of a cracking labor market signals a <a href="https://www.benzinga.com/markets/economic-data/25/08/46792479/july-nonfarm-payrolls-trump-powell-labor-market">looming recession</a>. 
This directly implies a future of potentially slowing loan demand and, more critically, potentially rising loan defaults from consumers and businesses, threatening the bank&#8217;s core profitability.
Compounding these economic fears, the market is now aggressively pricing in Federal Reserve rate cuts to combat the slowdown. The 2-year <a href="https://www.benzinga.com/news/treasuries">Treasury yield</a> plunged roughly 18 basis points to 3.78%, signaling that the lower interest rate environment expected to hurt bank profitability by compressing net interest margins is fast approaching.
The second major blow came from President Donald Trump&#8217;s <a href="https://www.benzinga.com/markets/macro-economic-events/25/08/46805962/trump-russia-medvedev-nuclear-submarines-vix-index-wall-street">nuclear threat</a> toward Russia, which sent Wall Street&#8217;s &#8220;fear gauge,&#8221; the VIX, soaring 27%. In such a severe risk-off environment, investors dump economically sensitive stocks. 
As a pillar of the financial system, Bank of America is on the front lines of this flight to safety, with its stock sold off alongside the broader market as investors brace for heightened global uncertainty and economic fallout.
Benzinga Edge Rankings: An analysis using the <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a> stock ranking system, which provides four critical scores to evaluate a company&#8217;s investment profile, offers a more nuanced view of Bank of America. The data indicates the company&#8217;s primary strength lies in its growth prospects, earning a high Growth score of 76.04. 
The stock also possesses healthy Momentum with a score of 67.16, suggesting a solid recent price performance trend. However, its Quality score, a measure of financial health and profitability, is more average at 51.24.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BAC shares are trading lower by 3.56% to $45.64 Friday afternoon. The stock has a 52-week high of $49.30 and a 52-week low of $33.06.
Read Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/08/46802730/markets-today-wall-street-friday-gold-tariffs-donald-trump">Stocks Sell Off, Gold Rallies On Tariff Turmoil, Weak Jobs Data: What&#8217;s Moving Markets Friday?</a>
<h2 class="wp-block-heading">How To Buy BAC Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Bank of America&#8217;s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

Bank of America Stock Slides Amid Dual Shocks Of Recession Fears And Geopolitical Threats

Shares of Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) are trading lower Friday after the company reported its second-quarter 2025 <a href="https://www.benzinga.com/markets/earnings/25/07/46778551/enovix-stock-is-tumbling-thursday-whats-going-on">financial results on Thursday.</a>
What To Know: While the lithium-ion battery maker topped Wall Street estimates for both revenue and earnings, the stock is under pressure as investors react to broader concerns around execution, cash burn and the path to mass commercialization.
Enovix reported revenue of $7.47 million for the second quarter, beating analyst expectations of $5.57 million. Adjusted earnings showed a loss of 13 cents per share, which was narrower than the projected 17-cent loss. Year-over-year, revenue nearly doubled, climbing 98% on the back of what the company called "strong demand" for its advanced battery technology.
In a letter to shareholders, the company highlighted the launch of its AI-1 battery platform, which features advanced materials and a fully automated manufacturing process. Enovix said it had finalized the platform, shipped production samples for qualification and delivered its third consecutive quarter of positive gross margins. The company also stated that it is entering the commercialization phase with mass production ramping up and new customers beginning qualification processes.
Despite these milestones, the stock sold off heavily in both after-hours and regular trading sessions. Investor concern appears centered on the company&#8217;s long-term execution risks and the steep losses still anticipated. For the third quarter, Enovix expects revenue between $7.5 million and $8.5 million, slightly ahead of the $7.3 million estimate, but it also guided for a loss of 14 to 18 cents per share, matching or just slightly better than current expectations.
Enovix ended the quarter with $203.4 million in cash, cash equivalents, and short-term investments, which gives it a cushion for continued development, but investors appear to be looking for clearer signs of scaled commercial deployment and sustained profitability.
The sharp drop in share price reflects a disconnect between solid quarterly metrics and lingering doubts about the company&#8217;s ability to execute its long-term growth plan in a competitive battery market.
ENVX Price Action: Enovix shares were down 16.5% at $11.19 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/08/46805962/trump-russia-medvedev-nuclear-submarines-vix-index-wall-street">Trump Issues Nuclear Threat To Russia–And Wall Street&#8217;s Fear Gauge Goes Vertical</a></li>
</ul>
Image Via Shutterstock.

ENVX

Enovix Shares Plunge Over 20% Despite Beating Q2 Revenue And EPS Estimates

Press Releases

TruGolf Links Celebrates 1-Year Anniversary at New York International Franchise Expo

TruGolf Announces Stock Repurchase Program

TruGolf Announces Listing Extension from Nasdaq

TruGolf to Paricipate in the "2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow" Conference Presented by Maxim Group LLC on Wednesday, June 4th at 3:00 PM EDT

TruGolf to Participate in the "2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow" Conference Presented by Maxim Group LLC on Wednesday, June 4th at 3:00 PM EDT - (Updated)

TruGolf Announces Acquisition of mlSpatial

TruGolf Announces Reverse Stock Split

Entertainment

URBAN EDGE SIGNS TRUGOLF FOR REVAMPED PLAZA AT CHERRY HILL

TruGolf Announces Portable Launch Monitor, LaunchBox, Available Globally on July 1st

TruGolf Announces Grand Opening of First TruGolf Links Franchise Location in Illinois

Blue Hat Interactive Entertainment Technology - Ordinary Shares

Blue Hat Interactive

DoubleDown Interactive Co., Ltd. - American Depository Shares

DoubleDown Interactive Co

DouYu International Holdings Limited - American Depositary Shares

DouYu Intl Hldgs

Electronic Arts

GCL Global Holdings Ltd - Ordinary Shares

GCL Global Holdings

GDEV

Golden Matrix Group

Gamehaus Holdings Inc. - Class A Ordinary Shares

Gamehaus Holdings

GRAVITY Co., Ltd. - American depositary shares, each representing one common share.

GRAVITY Co

Gaxos.AI

HUYA Inc. American depositary shares, each representing one Class A ordinary share

HUYA

iHuman Inc. American depositary shares, each representing five Class A ordinary shares

iHuman

Motorsport Games Inc. - Class A Common Stock

Motorsport Games

PLAYSTUDIOS

NetEase, Inc. - American Depositary Shares, each representing 5 ordinary shares

NetEase

Playtika Holding

Roblox

Sea Limited American Depositary Shares, each representing one Class A Ordinary Share

Comments

TruGolf Holdings

TruGolf Holdings (TRUG) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL